Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates

Core Insights - Orthofix reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.46 per share a year ago, indicating a 52.94% earnings surprise [1] - The company achieved revenues of $193.65 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.87% and showing a year-over-year increase from $188.61 million [2] - Orthofix shares have declined approximately 22.5% year-to-date, contrasting with the S&P 500's decline of 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.08, with projected revenues of $204 million, and for the current fiscal year, the EPS estimate is $0.62 on revenues of $823.9 million [7] - The estimate revisions trend for Orthofix is currently favorable, leading to a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Orthofix belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a strong performance potential [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]